BR112013003587A8 - proteínas osteogênicas designer - Google Patents

proteínas osteogênicas designer

Info

Publication number
BR112013003587A8
BR112013003587A8 BR112013003587A BR112013003587A BR112013003587A8 BR 112013003587 A8 BR112013003587 A8 BR 112013003587A8 BR 112013003587 A BR112013003587 A BR 112013003587A BR 112013003587 A BR112013003587 A BR 112013003587A BR 112013003587 A8 BR112013003587 A8 BR 112013003587A8
Authority
BR
Brazil
Prior art keywords
designer
proteins
osteogenic proteins
osteogenic
bmps
Prior art date
Application number
BR112013003587A
Other languages
English (en)
Other versions
BR112013003587B1 (pt
BR112013003587A2 (pt
Inventor
Todd Brown Christopher
Joel Seeherman Howard
Martin Wozney John
John Cain Michael
Vicent Paul Martinez Robert
Peter Berasi Stephen
Perrine Calabro Valerie
Sean Juo Zong
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013003587(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BR112013003587A2 publication Critical patent/BR112013003587A2/pt
Publication of BR112013003587A8 publication Critical patent/BR112013003587A8/pt
Publication of BR112013003587B1 publication Critical patent/BR112013003587B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Abstract

proteínas osteogênicas designer. a invenção refere-se às novas proteínas osteogênicas designer tendo afinidade alterada para um receptor cognato, ácidos nucleicos codificano as mesmas, e métodos de uso das mesmas. mais preferivelmente, as novas proteínas osteogênicas designer são bmps designer e têm afinidade alterada para um receptor de bmp cognato. as bmps designer demonstram características biológicas alteradas e fornecem novos terapêuticos úteis potenciais.
BR112013003587-0A 2010-08-20 2011-08-17 Proteínas osteogênicas projetadas, seus usos, seu método de produção e molécula de ácido nucleico isolada BR112013003587B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37563610P 2010-08-20 2010-08-20
US61/375,636 2010-08-20
PCT/IB2011/053638 WO2012023113A2 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins

Publications (3)

Publication Number Publication Date
BR112013003587A2 BR112013003587A2 (pt) 2016-06-07
BR112013003587A8 true BR112013003587A8 (pt) 2017-12-26
BR112013003587B1 BR112013003587B1 (pt) 2022-11-08

Family

ID=44720059

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003587-0A BR112013003587B1 (pt) 2010-08-20 2011-08-17 Proteínas osteogênicas projetadas, seus usos, seu método de produção e molécula de ácido nucleico isolada

Country Status (18)

Country Link
US (1) US8952131B2 (pt)
EP (4) EP2605787B1 (pt)
JP (4) JP5985480B2 (pt)
KR (3) KR101800596B1 (pt)
CN (2) CN105198981B (pt)
AR (1) AR082502A1 (pt)
AU (1) AU2011292810B2 (pt)
BR (1) BR112013003587B1 (pt)
CA (1) CA2807343C (pt)
CO (1) CO6680686A2 (pt)
HK (1) HK1184377A1 (pt)
IL (3) IL224394A (pt)
MX (1) MX2013001977A (pt)
PE (1) PE20140135A1 (pt)
RU (1) RU2013104029A (pt)
SG (1) SG187589A1 (pt)
TW (1) TWI444475B (pt)
WO (1) WO2012023113A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
EP2784083A1 (en) * 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
US9872881B2 (en) * 2013-11-01 2018-01-23 The Brigham And Women's Hospital, Inc. Bone and metal targeted polymeric nanoparticles
US10130678B2 (en) * 2014-12-29 2018-11-20 Bioventus, LLC. Systems and methods for improved delivery of osteoinductive molecules in bone repair
JP2018522540A (ja) 2015-06-05 2018-08-16 ノバルティス アーゲー 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法
WO2017032853A2 (en) * 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
CA2995310A1 (en) 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
BR112018007883A2 (pt) 2015-10-23 2018-10-30 Bioventus Llc purificação melhorada de proteínas da superfamíilia tgf-beta
WO2017196742A1 (en) 2016-05-09 2017-11-16 Bioventus, Llc Composite matrices designed for enhanced bone repair
KR20190018671A (ko) 2016-06-10 2019-02-25 바이오벤터스 엘엘씨 다공성 금속성 구조물에 의한 단백질 전달
KR102559539B1 (ko) 2016-07-20 2023-07-26 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
CN106749606B (zh) 2016-12-29 2018-06-22 广州领晟医疗科技有限公司 一种用于修复软骨和/或治疗骨关节炎的肽
CA3044371C (en) * 2016-12-30 2024-01-16 Biogend Therapeutics Co., Ltd. Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof
ES2908252T3 (es) 2017-11-24 2022-04-28 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de ALK-2
US11529438B2 (en) 2018-06-25 2022-12-20 Bioventus, Llc Porous carrier matrix

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6432919B1 (en) 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5459047A (en) 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5688678A (en) 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
WO1992000382A1 (en) 1990-06-15 1992-01-09 Carnegie Institution Of Washington Gdf-1
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5652337A (en) 1991-03-11 1997-07-29 Creative Biomolecules, Inc. OP-3-induced morphogenesis
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6025475A (en) 1998-09-15 2000-02-15 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
EP0690873B1 (en) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
PT1378572E (pt) 1993-05-12 2007-01-31 Genetics Inst Composições de bmp-11
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
WO1995010539A1 (en) 1993-10-08 1995-04-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
DE69723429T3 (de) 1996-03-22 2007-09-20 Curis, Inc., Cambridge Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
AU1103900A (en) * 1998-10-07 2000-04-26 Stryker Corporation Modified tgf-beta superfamily proteins
EP1150726B1 (en) 1999-02-04 2003-11-05 SDGI Holdings, Inc. Highly-mineralized osteogenic sponge compositions, and uses thereof
US7435260B2 (en) 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
DE10026713A1 (de) 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
EP1335686B1 (en) 2000-10-24 2008-12-17 Warsaw Orthopedic, Inc. Spinal fusion devices
EP1571159A1 (en) * 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
AU2005230854A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc BMP-7 variants with improved properties
AU2005247871A1 (en) 2004-04-27 2005-12-08 Research Development Foundation Antagonism of TGF-beta superfamily receptor signaling
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7749268B2 (en) 2004-05-26 2010-07-06 Warsaw Orthopedic, Inc. Methods for treating the spine
WO2005118636A2 (en) 2004-05-27 2005-12-15 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
EP1828232A2 (en) 2004-12-22 2007-09-05 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
US7910552B2 (en) 2005-05-27 2011-03-22 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
US7671014B2 (en) 2006-08-14 2010-03-02 Warsaw Orthopedic, Inc. Flowable carrier matrix and methods for delivering to a patient
WO2008051526A2 (en) 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
EP2222696A1 (en) 2007-12-21 2010-09-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
GB0818255D0 (en) * 2008-10-06 2008-11-12 Agency Science Tech & Res Isolation and identification of glycosaminoglycans
EP2401293B1 (en) 2009-02-24 2016-02-10 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
WO2011025042A1 (ja) 2009-08-31 2011-03-03 新日本製鐵株式会社 高強度溶融亜鉛めっき鋼板及びその製造方法

Also Published As

Publication number Publication date
EP2605787B1 (en) 2017-04-26
KR20160062191A (ko) 2016-06-01
JP2017029143A (ja) 2017-02-09
BR112013003587B1 (pt) 2022-11-08
AU2011292810A1 (en) 2013-02-07
CN103079585B (zh) 2015-09-30
SG187589A1 (en) 2013-03-28
EP3124039A2 (en) 2017-02-01
WO2012023113A3 (en) 2012-04-12
IL254186A0 (en) 2017-10-31
JP5985480B2 (ja) 2016-09-06
BR112013003587A2 (pt) 2016-06-07
EP3124039B1 (en) 2018-01-31
AU2011292810B2 (en) 2015-04-30
CA2807343C (en) 2018-05-22
CO6680686A2 (es) 2013-05-31
IL261608A (en) 2018-10-31
US20120046227A1 (en) 2012-02-23
TWI444475B (zh) 2014-07-11
JP2018126148A (ja) 2018-08-16
CN103079585A (zh) 2013-05-01
KR101800596B1 (ko) 2017-11-22
EP3124039A3 (en) 2017-03-08
CA2807343A1 (en) 2012-02-23
CN105198981A (zh) 2015-12-30
EP3320913B1 (en) 2019-11-27
EP2949338A1 (en) 2015-12-02
JP2016196478A (ja) 2016-11-24
WO2012023113A2 (en) 2012-02-23
KR20170094549A (ko) 2017-08-18
MX2013001977A (es) 2013-04-03
PE20140135A1 (es) 2014-02-20
KR101767860B1 (ko) 2017-08-14
RU2013104029A (ru) 2014-09-27
EP3320913A2 (en) 2018-05-16
IL261608B (en) 2019-05-30
HK1184377A1 (zh) 2014-01-24
EP2949338B1 (en) 2017-10-25
EP3320913A3 (en) 2018-07-25
AR082502A1 (es) 2012-12-12
IL224394A (en) 2017-11-30
EP2605787A2 (en) 2013-06-26
TW201226565A (en) 2012-07-01
KR101630501B1 (ko) 2016-06-15
JP6142041B2 (ja) 2017-06-07
KR20130048782A (ko) 2013-05-10
CN105198981B (zh) 2019-07-16
US8952131B2 (en) 2015-02-10
JP2013538054A (ja) 2013-10-10
JP6317789B2 (ja) 2018-04-25

Similar Documents

Publication Publication Date Title
BR112013003587A8 (pt) proteínas osteogênicas designer
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
CR20110245A (es) Mutantes fgf21 y uso de los mismos.
BR112013023006A8 (pt) formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112013026883A2 (pt) Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
BRPI0810863A2 (pt) Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease.
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
PE20160718A1 (es) Polipeptidos mutantes fgf21
BRPI0817811A2 (pt) Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
BRPI0921320A2 (pt) composições de anticorpo estáveis e métodos para estabilizar os mesmos
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112012032979A2 (pt) composição para limpeza límpida, de baixa irritação, e com ph relativamente baixo
BR112016029388A2 (pt) métodos, reagentes e células para biossintetizar compostos
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
BR112013009083A2 (pt) anticorpos humanos de oncostatin m e métodos de uso
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.